



Paediatric Clinical Research Infrastructure Network

Procedures for the setup of neonatal trials

Assessment of long-term outcome of neonatal trials:

Points to consider

V 1.0, 22 March 2021

Description	This tool lists examples of data items for the assessment long-term efficacy and safety outcome of neonatal trials
Key words	Neonatal trial, Protocol development, Guidance document, Tool, Long-term outcome

Authors: Beate Aurich, Valéry Elie,
Naura Mahmoudi, Evelyne Jacqz-Aigrain



Disclaimer: Sponsors and researchers unfamiliar with clinical trials in neonates and/or neonatology are advised to seek expert advice due the complexity of neonatology.

Correspondence email: pedcrin@ecrin.org



PedCRIN has received funding from the European Union's Horizon 2020 programmer under grant agreement number 731046

Introduction

Clinical trial outcome is defined as a patient's response to an intervention, for example treatment with an antibiotic.^{1,2} It can be assessed in a variety of ways including pharmacokinetics, pharmacodynamics, efficacy and safety using clinical and/or biological parameters.^{1,3} It is recorded for all patients independent of treatment allocation (active and control arm) and can be subjective or objective.¹ Outcome can be assessed by health care providers, patients and observers (i.e. parents) using standardised, validated methods.^{1,4} Outcome may vary between different neonatal diseases and also between neonatal intensive care units (NICU).⁵ Efficacy and safety outcomes influence the evaluation of the benefit-risk ratio of treatment.⁶⁻⁸ Research into neonatal outcome is currently conducted by a variety of initiatives including for example Core Outcomes in Neonates (COIN).⁹

Factors influencing neonatal outcome

Risk factors for severe adverse neonatal outcome (SANO) include for example prematurity (below 37 weeks of completed gestation) and abnormal birth weight (below 2500 gram or above 4000 gram), and can have different underlying aetiologies.¹⁰⁻¹⁶ Other risk factors include congenital disease, in-utero exposure to maternal disease and medications as well as complications during delivery.^{11,12,17,18}

Maternal factors and complications during delivery

Maternal diseases and complications during pregnancy and delivery can be risk factors for SANO.¹⁹ During protocol development for multicentre trials consideration might be given to potential differences in the type and frequency of diseases in women of child bearing potential in different populations.^{12,13}

Prematurity

Common conditions in preterm neonates (<37 weeks gestation) include for example sepsis, respiratory distress, intraventricular haemorrhage, hyperbilirubinaemia, persistent ductus arteriosus and necrotizing enterocolitis.^{15,16,20} Whilst premature delivery is considered to be a multi-factorial process, infections are thought to be a frequent cause of premature birth and may cause neonatal sepsis and mortality.²¹⁻²³ Neonates born prematurely may have more than one risk factor for morbidity and mortality. For example, a premature neonate born at 24 weeks gestation will have a birth weight below 2500 gram and may have, in addition, a congenital malformation. During protocol development consideration should be given to how gestational age is assessed and this should be included in the methods section of the protocol.²⁴

Birth weight

Both premature and term neonates may have a low birth weight.²⁵ Birth weight is routinely assessed correcting for gestational age and sex (percentile or z-score).^{26,27} Neonates with a birth weight below the 10th percentile (z-score below -2 standard deviations) for gestational age are considered small for gestational age (SGA).²⁶ Maternal hypertension, diabetes mellitus, chronic maternal infections and congenital diseases are for example associated with SGA.²⁷ These SGA neonates have a higher risk of morbidity and mortality including for example necrotizing enterocolitis, severe intraventricular haemorrhage, bronchopulmonary dysplasia, polycythaemia, hypoglycaemia, hyperbilirubinaemia and severe retinopathy of prematurity.²⁸⁻³⁰ Whilst low birth weight is associated with prematurity, it is an additional independent risk factor for adverse neonatal outcome.²⁵

Diabetes, excessive weight gain in pregnancy and a maternal body mass index above 25 are associated with a birth weight above 4000 gram and large for gestational age (LGA) babies (i.e. above the 90th percentile for gestational age; z-score above +2 standard deviations).^{26,31} LGA can also be associated with certain congenital syndromes.²⁶ LGA babies are at increased risk of birth injuries, respiratory distress, hyperbilirubinaemia, hypoglycaemia and polycythaemia.^{19,27}

Comorbidities

Examples of common morbidities observed in Neonatal Intensive Care Units (NICU) include infections, gastrointestinal, cardiac, intracranial and pulmonary diseases.^{32,33} Their aetiology is often multifactorial and they present clinically in a variety of ways. For example, symptoms of sepsis may include hyperbilirubinaemia, necrotizing enterocolitis, coagulopathy, hypoglycaemia and/or respiratory failure.^{28,34-36} Abnormal coagulation in turn increases the risk of intraventricular haemorrhage.³⁷

Comedications

The type and number of concomitant medicines are determined by the comorbidities, which in turn are influenced by the above mentioned risk factors for neonatal disease.^{16,29} In addition, drug-drug interactions and drug-disease interactions should be considered because they may influence outcome.^{38,39} The frequency of off-label/unlicensed use of medicines and medication errors as well as issues with the provision of age adapted formulations in NICU should be taken into account.⁴⁰⁻⁴² Off-label and unlicensed use of medicines is associated with a higher risk of adverse drug reactions and medication errors.^{43,44} Additional factors, which may modify outcome, include for example possible differences between different NICUs in treatment protocols for comorbidities (i.e. criteria for initiating treatment, the specific drugs used, doses, frequency and duration of therapy).^{45,46} It is important to address these potential differences at the time of protocol writing and trial set up in order to reduce bias and confounding.⁴⁷⁻⁵³

Long-term outcome and follow-up of neonatal trials: Points to consider

The definition of long-term outcome is a matter of debate.⁵⁴ The duration of follow-up is influenced by the study objectives (efficacy and safety) and the estimated delay with which these outcomes will present clinically, taking into consideration how child development influences the measurement of outcome.^{48,55,56} For example, a diagnosis of attention deficit hyperactivity disorder (ADHD) is difficult to make before the age of 4 years, because it is not possible to distinguish age appropriate behaviour, such as a short attention span, from ADHD related symptoms.⁵⁷ Furthermore, the length of follow-up is influenced by estimates of loss to follow-up and how this may introduce bias.⁵⁸ Disease registries might be considered for studying long-term outcome.⁵⁹

In Europe, most neonates admitted to NICU are followed-up by the NICU team after discharge for at least several months and will have a general practitioner or paediatrician looking after them throughout childhood. Follow-up should be timed with routine paediatric check-ups (i.e. developmental assessments, vaccinations) and usually include a standardised neurodevelopmental and growth assessment.⁶⁰⁻⁶³ Table 1 provides examples of data items which might inform the assessment of long-term outcome in neonatal trials.

Conclusions

Assessing outcome in neonates is complex. Key factors influencing neonatal outcome include, for example, maternal disease, in-utero drug exposure, birth weight, gestational age at birth, comorbidities and comedications. Therefore, analysis of clinical trial data needs to be stratified by risk factors and confounders for outcome. The methods of neonatal outcome assessment, including the duration of follow up, for both efficacy and safety, need careful consideration as they may differ considerably from older children and adults.

Competing interests

All authors consider not having any competing interests for this tool. BA has worked for GlaxoSmithKline between October 2006 and September 2009 and holds company shares. Between October 2009 and May 2015 she has worked for Novartis.

References

1. International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH). ICH Harmonised Tripartite Guideline – General considerations for clinical trials E8, Current Step 4 version, 17 July 1997, Geneva. Available at: https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E8/Step4/E8_Guideline.pdf
2. International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH). ICH Harmonised Tripartite Guideline – Statistical principles for clinical trials E9, Current Step 4 version, 5 February 1998, Geneva. Available at: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E9/Step4/E9_Guideline.pdf
3. Food and Drug Administration (FDA), National Institutes of Health (NIH). BEST (Biomarkers, EndpointS, and other Tools) Resource.2 May 2018, Silver Spring. Available at: https://www.ncbi.nlm.nih.gov/books/NBK326791/pdf/Bookshelf_NBK326791.pdf
4. Food and Drug Administration (FDA). Clinical Outcome Assessment Compendium, Version 1, 31 December 2015, Silver Spring. Available at: <https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm459231.htm>
5. Clarke P, Webber MA. Catheter sepsis and antisepsis: matters of life, death, obscurity and resistance. *Arch Dis Child Fetal Neonatal Ed.* 2018 Mar;103(2):F94-F96. doi: 10.1136/archdischild-2017-313150.
6. International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH). ICH Tripartite Guidelines - Clinical investigation of medicinal products in the pediatric population E11, Current Step 4 version, 20 July 2000, Geneva. Available at: https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/guidelines/Efficacy/E11/Step4/E11_Guidelines.pdf
7. Council for International Organizations of Medical Sciences (CIOMS). Benefit-Risk Balance for Marketed Drugs: Evaluating Safety Signals - Report of CIOMS Working Group IV. CIOMS 1998, Geneva. Available at: <https://cioms.ch/wp-content/uploads/2017/01/benefit-risk.pdf>
8. Kirkham JJ, Gorst S, Altman DG, Blazeby JM, Clarke M, Devane D, et al. Core Outcome Set-STAndards for Reporting: The COS-STAR Statement. *PLoS Med.* 2016 Oct 18;13(10):e1002148. doi: 10.1371/journal.pmed.1002148. eCollection 2016 Oct.
9. Webbe J, Brunton G, Ali S, Duffy JM, Modi N, Gale C. Developing, implementing and disseminating a core outcome set for neonatal medicine. *BMJ Paediatr Open.* 2017 Jul 26;1(1):e000048. doi: 10.1136/bmjpo-2017-000048.
10. International Federation of Gynecology and Obstetrics (FIGO). WHO: recommended definitions, terminology and format for statistical tables related to the perinatal period and use of a new certificate for cause of perinatal deaths. Modifications recommended by FIGO as amended October 14, 1976. *Acta Obstet Gynecol Scand.* 1977;56(3):247–53. doi: 10.3109/00016347709162009.
11. Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. *Lancet.* 2008 Jan 5;371(9606):75-84. doi: 10.1016/S0140-6736(08)60074-4.
12. Mohangoo AD, Buitendijk SE, Szamotulska K, Chalmers J, Irgens LM, Bolumar F, Nijhuis JG, Zeitlin J; Euro-Peristat Scientific Committee. Gestational age patterns of fetal and neonatal mortality in Europe: results from the Euro-Peristat project. *PLoS One.* 2011;6(11):e24727. doi: 10.1371/journal.pone.0024727.
13. Mohangoo AD, Blondel B, Gissler M, Velebil P, Macfarlane A, Zeitlin J; Euro-Peristat Scientific Committee. International comparisons of fetal and neonatal mortality rates in high-income countries: should exclusion thresholds be based on birth weight or gestational age? *PLoS One.* 2013 May 20;8(5):e64869. doi: 10.1371/journal.pone.0064869.
14. Kramer MS, Demissie K, Yang H, Platt RW, Sauvé R, Liston R. The contribution of mild and moderate preterm birth to infant mortality. Fetal and Infant Health Study Group of the Canadian Perinatal Surveillance System. *JAMA.* 2000 Aug 16;284(7):843-9.
15. McIntire DD, Leveno KJ. Neonatal mortality and morbidity rates in late preterm births compared with births at term. *Obstet Gynecol.* 2008 Jan;111(1):35-41. doi: 10.1097/01.AOG.0000297311.33046.73.



16. Manuck TA, Rice MM, Bailit JL, Grobman WA, Reddy UM, Wapner RJ, et al. Preterm neonatal morbidity and mortality by gestational age: a contemporary cohort. *Am J Obstet Gynecol.* 2016 Jul;215(1):103.e1-103.e14. doi: 10.1016/j.ajog.2016.01.004.
17. Marlow N, Wolke D, Bracewell MA, Samara M, EPICure Study group. Neurologic and developmental disability at six years of age after extremely preterm birth. *N Engl J Med* 2005;352:9-19.
18. Linhart Y, Bashiri A, Maymon E, Shoham-Vardi I, Furman B, Vardi H, et al. Congenital anomalies are an independent risk factor for neonatal morbidity and perinatal mortality in preterm birth. *Eur J Obstet Gynecol Reprod Biol.* 2000 May;90(1):43-9.
19. Fadl HE, Ostlund IK, Magnuson AF, Hanson US. Maternal and neonatal outcomes and time trends of gestational diabetes mellitus in Sweden from 1991 to 2003. *Diabet Med.* 2010 Apr;27(4):436-41. doi: 10.1111/j.1464-5491.2010.02978.x.
20. Benitz WE; Committee on Fetus and Newborn, American Academy of Pediatrics. Patent Ductus Arteriosus in Preterm Infants. *Pediatrics.* 2016 Jan;137(1). doi: 10.1542/peds.2015-3730.
21. Glover AV, Manuck TA. Screening for spontaneous preterm birth and resultant therapies to reduce neonatal morbidity and mortality: A review. *Semin Fetal Neonatal Med.* 2018 Apr;23(2):126-132. doi: 10.1016/j.siny.2017.11.007.
22. Parnell LA, Briggs CM, Mysorekar IU. Maternal microbiomes in preterm birth: Recent progress and analytical pipelines. *Semin Perinatol.* 2017 Nov;41(7):392-400. doi: 10.1053/j.semperi.2017.07.010.
23. March of Dimes, the Partnership for Maternal, Newborn and Child Health, Save the Children, World Health Organisation (WHO). Born Too Soon: The Global Action Report on Preterm Birth. World Health Organization, 2 May 2012, New York. Available at: https://www.who.int/pmnch/media/news/2012/preterm_birth_report/en/
24. Lee AC, Panchal P, Folger L, Whelan H, Whelan R, Rosner B, et al. 17. Diagnostic Accuracy of Neonatal Assessment for Gestational Age Determination: A Systematic Review. *Pediatrics.* 2017 Dec;140(6). pii: e20171423. doi: 10.1542/peds.2017-1423.
25. Lemons JA, Bauer CR, Oh W, Korones SB, Papile LA, Stoll BJ, et al. Very low birth weight outcomes of the National Institute of Child health and human development neonatal research network, January 1995 through December 1996. NICHD Neonatal Research Network. *Pediatrics.* 2001 Jan;107(1):E1.
26. Romero R, Tarca AL. Fetal size standards to diagnose a small- or a large-for-gestational-age fetus. *Am J Obstet Gynecol.* 2018 Feb;218(2S):S605-S607. doi: 10.1016/j.ajog.2017.12.217.
27. Mayer C, Joseph KS. Fetal growth: a review of terms, concepts and issues relevant to obstetrics. *Ultrasound Obstet Gynecol.* 2013 Feb;41(2):136-45. doi: 10.1002/uog.11204.
28. Yee WH, Soraisham AS, Shah VS, Aziz K, Yoon W, Lee SK, et al. Incidence and timing of presentation of necrotizing enterocolitis in preterm infants. *Pediatrics.* 2012 Feb;129(2):e298-304. doi: 10.1542/peds.2011-2022.
29. Jensen EA, Foglia EE, Dysart KC, Simmons RA, Aghai ZH, Cook A, et al. Adverse effects of small for gestational age differ by gestational week among very preterm infants. *Arch Dis Child Fetal Neonatal Ed.* 2018 May 5. pii: fetalneonatal-2017-314171. doi: 10.1136/archdischild-2017-314171.
30. Lee AC, Kozuki N, Cousens S, Stevens GA, Blencowe H, Silveira MF, et al. Estimates of burden and consequences of infants born small for gestational age in low and middle income countries with INTERGROWTH-21st standard: analysis of CHERG datasets. *BMJ.* 2017 Aug 17;358:j3677. doi: 10.1136/bmj.j3677.
31. Kim SY, Sharma AJ, Sappenfield W, Wilson HG, Salihu HM. Association of maternal body mass index, excessive weight gain, and gestational diabetes mellitus with large-for-gestational-age births. *Obstet Gynecol.* 2014 Apr;123(4):737-44. doi: 10.1097/AOG.0000000000000177.
32. Ancel PY, Goffinet F; EPIPAGE-2 Writing Group, Kuhn P, Langer B, Matis J, et al. Survival and morbidity of preterm children born at 22 through 34 weeks' gestation in France in 2011: results of the EPIPAGE-2 cohort study. *JAMA Pediatr.* 2015 Mar;169(3):230-8. doi: 10.1001/jamapediatrics.2014.3351.
33. Miltenburg AS, van Elburg RM, Kostense PJ, van Geijn HP, Bolte AC. Neonatal morbidity in term neonates is related to gestational age at birth and level of care. *J Perinat Med.* 2011 Sep;39(5):605-10. doi: 10.1515/JPM.2011.070.
34. Gephart SM, McGrath JM, Effken JA, Halpern MD. Necrotizing enterocolitis risk: state of the science. *Adv Neonatal Care.* 2012 Apr;12(2):77-87; quiz 88-9. doi: 10.1097/ANC.0b013e31824cee94.
35. Mautone A, Giordano P, Montagna O, Quercia M, Altomare M, De Mattia D. Coagulation and fibrinolytic systems in the ill preterm newborn. *Acta Paediatr.* 1997 Oct;86(10):1100-4.
36. Del Vecchio A, Stronati M, Franco C, Christensen RD. Bi-directional activation of inflammation and coagulation in septic neonates. *Early Hum Dev.* 2014 Mar;90 Suppl 1:S22-5. doi: 10.1016/S0378-3782(14)70008-8.



37. Duppré P, Sauer H, Giannopoulou EZ, Gortner L, Nunold H, Wagenpfeil S, et al. Cellular and humoral coagulation profiles and occurrence of IVH in VLBW and ELWB infants. *Early Hum Dev.* 2015 Dec;91(12):695-700. doi: 10.1016/j.earlhumdev.2015.09.008.
38. European Medicines Agency (EMA), Committee for Human Medicinal Products (CHMP). Guideline on the investigation of drug interactions. 21 June 2012, CPMP/EWP/560/95/Rev. 1 Corr. 2**, London. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129606.pdf
39. Grissinger M. The Absence of a Drug-Disease Interaction Alert Leads to a Child's Death. *P T.* 2018 Feb;43(2):71-72.
40. Horri J, Cransac A, Quantin C, Abrahamowicz M, Ferdynus C, Sgro C, et al. Frequency of dosage prescribing medication errors associated with manual prescriptions for very preterm infants. *J Clin Pharm Ther.* 2014 Dec;39(6):637-41. doi: 10.1111/jcpt.12194.
41. Jain L. The conundrum of off-label and unlicensed drug usage in neonatology. *J Pediatr (Rio J).* 2012 Nov-Dec;88(6):449-51. doi:10.2223/JPED.2243.
42. Allegaert K, Cosaert K, van den Anker JN. Neonatal Formulations: The Need for a Tailored, Knowledge Driven Approach. *Curr Pharm Des.* 2015;21(39):5674-9.
43. Choonara I, Conroy S. Unlicensed and off-label drug use in children: implications for safety. *Drug Saf.* 2002;25(1):1-5.
44. Sorrentino E, Alegiani C. Medication errors in the neonate. *J Matern Fetal Neonatal Med.* 2012 Oct;25 Suppl 4:91-3. doi: 10.3109/14767058.2012.714994.
45. Pandolfini C, Kaguelidou F, Sequi M, Jacqz-Aigrain E, Choonara I, Turner MA, et al. Wide intra- and inter-country variability in drug use and dosage in very-low-birth-weight newborns with severe infections. *Eur J Clin Pharmacol.* 2013 Apr;69(4):1031-6. doi: 10.1007/s00228-012-1415-2.
46. Flint RB, van Beek F, Andriessen P, Zimmermann LJ, Liem KD, Reiss IKM, et al. Large differences in neonatal drug use between NICUs are common practice: time for consensus? *Br J Clin Pharmacol.* 2018 Jun;84(6):1313-1323. doi: 10.1111/bcp.13563.
47. European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP), Paediatric Committee (PDCO). Guideline on the Investigation of Medicinal Products in the Term and Preterm Neonate. EMEA/536810/2008, London, 25 June 2009. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-medicinal-products-term-preterm-neonate-first-version_en.pdf
48. European Medicines Agency (EMA). Guideline on good pharmacovigilance practices (GVP) Product- or Population-Specific Considerations IV: Paediatric population. EMA/572054/2016, London, 25 October 2018. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-product-population-specific-considerations-iv_en-0.pdf
49. European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP). Guideline on Conduct of Pharmacovigilance for Medicines used by the Paediatric Population. EMEA/CHMP/PhVWP/235910/2005- rev.1, London, 25 January 2007. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-conduct-pharmacovigilance-medicines-used-paediatric-population_en.pdf
50. COIN. COIN Consensus Group Meeting 12th September 2018: Structured Minutes. Available at: <http://neoepoch.com/core-outcomes>
51. Barker CIS, Standing JF, Kelly LE, Hanly Fought L, Needham AC, Rieder MJ, et al. Pharmacokinetic studies in children: recommendations for practice and research. *Arch Dis Child.* 2018 Jul;103(7):695-702. doi: 10.1136/archdischild-2017-314506.
52. European Commission (EC). Ethical considerations for clinical trials on medicinal products conducted in the paediatric population. Recommendations of the adhoc group for the development of implementing guidelines for Directive 2001/20/EC relating to good clinical practice in the conduct of clinical trials on medicinal products for human use, London, 2006. Available at: https://ec.europa.eu/health/sites/health/files/files/paediatrics/docs/paeds_ethics_consultation_20060929_en.pdf
53. Snowdon C, Brocklehurst P, Tasker RC, Ward Platt M, Elbourne D. "You have to keep your nerve on a DMC." Challenges for Data Monitoring Committees in neonatal intensive care trials: Qualitative accounts from the BRACELET Study. *PLoS One.* 2018 Jul 26;13(7):e0201037. doi: 10.1371/journal.pone.0201037. eCollection 2018.
54. Hintz SR, Newman JE, Vohr BR. Changing definitions of long-term follow-up: Should "long term" be even longer? *Semin Perinatol.* 2016 Oct;40(6):398-409. doi: 10.1053/j.semperi.2016.05.011.
55. European Medicines Agency (EMA). Guideline on safety and efficacy follow-up – risk management of advanced therapy medicinal products. Doc. 20 November 2008, Ref. EMEA/149995/2008, London. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/10/WC500006326.pdf



56. European Medicines Agency (EMA), Committee for Human Medicinal Products (CHMP). Guideline on follow-up of patients administered gene therapy medicinal products. 22 October 2009, Doc. Ref. EMEA/CHMP/GTWP/60436/2007, London. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/11/WC500013424.pdf
57. McGoey KE, DuPaul GJ, Haley E, Shelton TL. Parent and Teacher Ratings of Attention-Deficit/Hyperactivity Disorder in Preschool: The ADHD Rating Scale-IV Preschool Version. *J Psychopathol Behav Assess* (2007) 29:269–276. DOI 10.1007/s10862-007-9048-y
58. Howe CJ, Cole SR, Lau B, Napravnik S, Eron JJ Jr. Selection Bias Due to Loss to Follow Up in Cohort Studies. *Epidemiology*. 2016 Jan;27(1):91-7. doi: 10.1097/EDE.0000000000000409.
59. Pfister RH, Bingham P, Edwards EM, Horbar JD, Kenny MJ, Inder T, Nelson KB, Raju T, Soll RF. The Vermont Oxford Neonatal Encephalopathy Registry: rationale, methods, and initial results. *BMC Pediatr*. 2012 Jun 22;12:84. doi: 10.1186/1471-2431-12-84.
60. Haslam MD, Lisonkova S, Creighton D, Church P, Yang J, Shah PS, et al. Severe Neurodevelopmental Impairment in Neonates Born Preterm: Impact of Varying Definitions in a Canadian Cohort. *J Pediatr*. 2018 Jun;197:75-81.e4. doi: 10.1016/j.jpeds.2017.12.020.
61. Maitre NL, Chorna O, Romeo DM, Guzzetta A. Implementation of the Hammersmith Infant Neurological Examination in a High-Risk Infant Follow-Up Program. *Pediatr Neurol*. 2016 Dec;65:31-38. doi: 10.1016/j.pediatrneurol.2016.09.010.
62. Fenton TR, Kim JH. A systematic review and meta-analysis to revise the Fenton growth chart for preterm infants. *BMC Pediatr*. 2013 Apr 20;13:59. doi: 10.1186/1471-2431-13-59.
63. World Health Organization (WHO). The WHO Child Growth Standards. Geneva 2016. Available from: www.who.int/childgrowth/standards/en/



Table 1. Examples of data items for the assessment of long-term outcome of neonatal trials

Type of outcome	Examples of long-term outcome	Examples of references
Efficacy		
Disease specific	Cure	1-3
	Worsening or recurrence	1-3
	Improvement (but not cured)	1-3
	Time to event (e.g. surgery)	1,2
	Quality of life following treatment	4
	Death due to disease being treated	1-3
Safety		
Drug/ intervention specific	ADRs (e.g. which present after discontinuation of the study drug or from which the patient has not fully recovered by the end of the trial or ADRs during chronic treatment)	5,6
	Interactions (e.g. during chronic treatment)	5,6
	Quality of life following an ADR	4
	Long-term sequelae of ADRs	5,6
	Death due to ADR or its sequelae	5,6
Overall		
	Development	3,7-9
	Growth	3,7,8,10
	Quality of life	3,4,7,8
	Morbidity	3,7,8,11,12
	Death (any cause)	3,7,8
References:		
<ol style="list-style-type: none"> European Medicines Agency (EMA). ICH Topic E 3 Structure and Content of Clinical Study Reports – Note for Guidance on structure and content of clinical Study Reports. CPMP/ICH/137/95, London, July 1996. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-3-structure-content-clinical-study-reports-step-5_en.pdf Schulz et al. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials <i>BMJ</i> 2010; 340: c332. European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP), Paediatric Committee (PDCO). Guideline on the Investigation of Medicinal Products in the Term and Preterm Neonate. EMEA/536810/2008, London, 25 June 2009. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-medicinal-products-term-preterm-neonate-first-version_en.pdf Roberts G. Quality of life after extremely preterm birth. <i>Arch Dis Child.</i> 2019 Apr;104(4):311-312. doi: 10.1136/archdischild-2018-315708. European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP). Guideline on Conduct of Pharmacovigilance for Medicines used by the Paediatric Population. EMEA/CHMP/PhVWP/235910/ 2005- rev.1, London, 25 January 2007. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-conduct-pharmacovigilance-medicines-used-paediatric-population_en.pdf European Medicines Agency (EMA). Guideline on good pharmacovigilance practices (GVP) Product- or Population-Specific Considerations IV: Paediatric population. EMA/572054/2016, London, 25 October 2018. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-product-population-specific-considerations-iv_en-0.pdf European Medicines Agency (EMA). ICH Topic E 11 Clinical Investigation of Medicinal Products in the Paediatric Population – Note for Guidance on Clinical Investigation of Medicinal Products in the Paediatric Population. CPMP/ICH/2711/99, London, January 2001. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use_en-30.pdf European Medicines Agency (EMA). ICH E11 (R1) guideline on clinical investigation of medicinal products in the pediatric population. EMA/CPMP/ICH/2711/1999, London, 1 September 2017. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e11r1-guideline-clinical-investigation-medicinal-products-pediatric-population-revision-1_en.pdf Berglund SK, Chmielewska A, Starnberg J, Westrup B, Hägglöf B, Norman M, et al. Effects of iron supplementation of low-birth-weight infants on cognition and behavior at 7 years: a randomized controlled trial. <i>Pediatr Res.</i> 2018 Jan;83(1-1):111-118. doi: 10.1038/pr.2017.235. 		

10. **Späth C**, Zamir I, Sjöström ES, Domellöf M. Use of concentrated parenteral nutrition solutions is associated with improved nutrient intakes and postnatal growth in Very Low-Birth-Weight Infants. *JPEN J Parenter Enteral Nutr.* 2019 Feb 12. doi: 10.1002/jpen.1522. [Epub ahead of print]
11. **Mohlkert LA**, Hallberg J, Broberg O, Rydberg A, Halvorsen CP, Liuba P, et al. The Preterm Heart in Childhood: Left Ventricular Structure, Geometry, and Function Assessed by Echocardiography in 6-Year-Old Survivors of Periviable Births. *J Am Heart Assoc.* 2018 Jan 20;7(2). pii: e007742. doi: 10.1161/JAHA.117.007742.
12. **Thunqvist P**, Tufvesson E, Bjermer L, Winberg A, Fellman V, Domellöf M, et al. Lung function after extremely preterm birth-A population-based cohort study (EXPRESS). *Pediatr Pulmonol.* 2018 Jan;53(1):64-72. doi: 10.1002/ppul.23919.

